Pay in 4 interest-free payments of $24.00 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
PubMed Central PMCID: PMC5507339
as well as effects on the cardiovascular and endocrine systems
and long-term treatment is well tolerated
Infect Immun
Canagliflozin inhibits Na+-dependent 14C-AMG uptake in CHO-hSGLT2 cells
Dapagliflozin chin gallate PubMed Central PMCID: PMC5507339Dapagliflozin, also known as BMS 512148, is a drug used to treat type 2 diabetes approved in 2012 by FDA. Dapagliflozin inhibits subtype 2 of the sodium glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. In clinical trials, dapagliflozin lowered HbA1c by 0. 6 versus placebo percentage points
US$ 20.79
US$ 89.74
US$ 21.47
US$ 315.85
US$ 12285.00
US$ 58.79